Mutations in chronic myelomonocytic leukemia and their prognostic relevance
Authors:
- 16 April 2021
- journal article
- review article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (9) , 1731-1742
Abstract
Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy that overlaps with myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) and tends to transform into acute myeloid leukemia (AML). Among cases of CMML, > 90% have gene mutations, primarily involving TET2 (~ 60%), ASXL1 (~ 40%), SRSF2 (~ 50%), and the RAS pathways (~ 30%). These gene mutations are associated with both the clinical phenotypes and the prognosis of CMML, special CMML variants and pre-phases of CMML. Cytogenetic abnormalities and the size of genome are also associated with prognosis. Meanwhile, cases with ASXL1, DNMT3A, NRAS, SETBP1, CBL and RUNX1 mutations may have inferior prognoses, but only ASXL1 mutations were confirmed to be independent predictors of the patient outcome and were included in three prognostic models. Novel treatment targets related to the various gene mutations are emerging. Therefore, this review provides new insights to explore the correlations among gene mutations, clinical phenotypes, prognosis, and novel drugs in CMML.Keywords
This publication has 92 references indexed in Scilit:
- SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemiasLeukemia, 2013
- SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Blood, 2012
- Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaHaematologica, 2012
- Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 casesHaematologica, 2012
- Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3ABlood, 2011
- Cytogenetic risk stratification in chronic myelomonocytic leukemiaHaematologica, 2010
- Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasmsNature, 2009
- CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome SubtypesClinical Cancer Research, 2009
- 250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid MalignanciesCancer Research, 2008
- Genome Regulation by Polycomb and Trithorax ProteinsCell, 2007